Alexandra M Stevens
Overview
Explore the profile of Alexandra M Stevens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bledsaw K, Prudowsky Z, Zobeck M, Robins J, Staton S, DeJean J, et al.
Jt Comm J Qual Patient Saf
. 2024 Sep;
50(11):784-790.
PMID: 39289143
Background: Mucosal barrier injury central line-associated bloodstream infections (MBI-CLABSIs) remain a challenge among the pediatric cancer population. These infections commonly occur by oral or gastrointestinal (GI) bacteria translocating through impaired...
2.
Davis A, Stevens A, Brackett J, Marquez L, Foster C, Sarmiento Clemente A, et al.
Antimicrob Steward Healthc Epidemiol
. 2024 May;
4(1):e90.
PMID: 38807931
Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and...
3.
Magee K, Robins J, Staton S, Llaurador G, Stevens A
Pediatr Blood Cancer
. 2024 Apr;
71(6):e30966.
PMID: 38556719
Background: Oral mucositis (OM) is a painful and common complication of hematopoietic stem cell transplant (HSCT). The Children's Oncology Group recently published guidelines recommending photobiomodulation (PBM) for preventing and treating...
4.
Stevens A, Terrell M, Rashid R, Fisher K, Marcogliese A, Gaikwad A, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397996
The survival rate of pediatric acute myeloid leukemia (pAML) is currently around 60%. While survival has slowly increased over the past few decades, the development of novel agents likely to...
5.
Strachan D, Gu C, Kita R, Anderson E, Richardson M, Yam G, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551725
Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for ~20% of all childhood leukemias, and more than 40% of children with AML relapse within three years of diagnosis....
6.
Horvath T, Poventud-Fuentes I, Olayinka L, James A, Haidacher S, Hoch K, et al.
J Mass Spectrom Adv Clin Lab
. 2022 Nov;
26:23-27.
PMID: 36388060
Background: Atovaquone has traditionally been used as an antiparasitic and antifungal agent, but recent studies have shown its potential as an anticancer agent. The high variability in atovaquone bioavailability highlights...
7.
Bledsaw K, Prudowsky Z, Yang E, Harriehausen C, Robins J, DeJean J, et al.
JCO Oncol Pract
. 2022 Sep;
19(1):e25-e32.
PMID: 36137251
Purpose: Pediatric oncology and bone marrow transplant patients are at high risk of infection, and limitations to dental expertise among medical providers render patients vulnerable to central line-associated bloodstream infections...
8.
Stevens A, Horton T, Glasser C, Gerbing R, Aplenc R, Alonzo T, et al.
Pediatr Hematol Oncol
. 2022 Jul;
40(2):147-158.
PMID: 35838057
Pediatric acute myeloid leukemia (AML) is a devastating disease with a high risk of relapse. Current risk classification designates patients as high or low risk (LR) based on molecular features...
9.
Schafer E, Chao K, Stevens A, Jo E, Hilsenbeck S, Gossai N, et al.
Pediatr Blood Cancer
. 2022 Jun;
69(10):e29812.
PMID: 35726868
Current therapies for relapsed/refractory (R/R) pediatric myeloid neoplasms are inadequately effective. Real-world data (RWD) can improve care by augmenting traditional studies and include individuals not eligible for clinical trials. The...
10.
Kurtz K, Tallis E, Marcogliese A, Pulivarthi R, Potocki L, Stevens A
Pediatr Hematol Oncol
. 2022 Mar;
39(8):747-754.
PMID: 35275800
Rubinstein-Taybi syndrome (RSTS) is a rare disorder characterized by developmental delay, short stature, dysmorphic facies and skeletal abnormalities. RSTS has been linked to a variety of malignant and benign tumors,...